OCS OCULIS HOLDING AG

Oculis Publishes Notification of Major Changes in Voting Rights

Oculis Publishes Notification of Major Changes in Voting Rights

ZUG, Switzerland, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Attached is a Notification of Major Changes in Voting Rights.

Attachment



EN
21/01/2025

Underlying

OCSOCULIS HOLDING AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OCULIS HOLDING AG

 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthal...

Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference ZUG, Switzerland, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential market of $7B+ in the U.S. aloneMultiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 eye drops in diabetic macular edema (DME) expected in Q2 2026 Riad Sherif, M.D., Chief Executive Officer, ...

January 8, 2026 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthal...

Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential market of $7B+ in the U.S. aloneMultiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 eye drops in diabetic macular edema (DME) expected in Q2 2026 Riad Sherif, M.D., Chief Executive Officer, will present at the J.P. Morgan Healthcare Conference ...

January 8, 2026 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to ...

Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritisPrivosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S.Privosegtor achieved an average gain in Low Contrast Visual Acuity (LCVA) of 18 letters compared to IV steroid alone at month 3 in the ACUITY ...

January 6, 2026 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to ...

Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average gain in Low Contrast Visual Acuity (LCVA) of 18 letters compared to IV steroid alone at month 3 in the ACU...

January 6, 2026 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis tilkynnir um að Matvæla- og lyfjastofnun Bandaríkjanna (FDA) ha...

Oculis tilkynnir um að Matvæla- og lyfjastofnun Bandaríkjanna (FDA) hafi veitt Privosegtor stöðu byltingarkennds meðferðarlyfs til meðhöndlunar á sjóntaugabólgu ZUG, Sviss, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Taugaverndandi þróunarlyfið Privosegtor hefur fengið stöðu byltingarkennds meðferðarlyfs (e. Breakthrough Therapy Designation) til meðhöndlunar á sjóntaugabólgu Framþróun Privosegtor heldur áfram, í PIONEER-skráningaráætluninni, sem möguleg meðferð við tvenns konar sjóntaugakvillum sem hafa mögulegt markaðstækifæri upp á 7 milljarða USD í Bandaríkjunum. Privosegtor náði að meðaltali ...

January 6, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch